Zelira Therapeutics (DE:G1G)
FRANKFURT:G1G
G1G Stock Chart & Stats
€0.18
€0.00(0.00%)
At close: 4:00 PM EST
€0.18
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.17 - €0.51
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.62M
Enterprise Value€8.08M
Total Cash (Recent Filing)€5.66K
Total Debt (Recent Filing)€2.14M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Monetization StrategyZelira's dual monetization model — direct product commercialization plus licensing/co-development — provides multiple durable revenue levers. Licensing and partnerships are capital-efficient and can scale IP value independently of product sales, offering structural optionality if one channel underperforms.
Focus On Cannabinoid Therapeutics And Consumer HealthOperating in cannabinoid therapeutics and wellness ties Zelira to a structurally growing market for medicinal cannabis and health products. Proprietary formulations and R&D expertise create enduring product differentiation and enable future licensing or commercial rollouts as regulatory acceptance expands.
Slight Improvement In Free Cash Flow GrowthAlthough cash flows remain negative, the noted slight improvement in free cash flow growth indicates initial progress on cash discipline. If sustained, this trend can materially extend runway and reduce near-term financing needs, supporting execution of commercialization or licensing plans.
Bears Say
Severe Revenue Decline And Negative MarginsA ~98% revenue collapse combined with negative gross, net and EBIT margins signals loss of core commercial traction and an unprofitable operating model. Over the medium term this undermines scalability, increases dependency on external funding, and weakens the firm's ability to commercialize or support R&D investments.
Negative Shareholders' EquityNegative equity reflects balance-sheet instability and can restrict access to debt or favorable financing, elevating insolvency risk. Structurally, it reduces financial flexibility to invest in product launches or partnerships and may compel dilutive capital raises that impair long-term shareholder value.
Ongoing Negative Operating Cash FlowsPersistent negative operating cash flow indicates the business burns cash to run operations and cannot self-fund growth. Even with slight FCF improvement, ongoing cash deficits force reliance on external capital or spending cuts, structurally limiting R&D and commercialization over the next several months.
Zelira Therapeutics News
G1G FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was €0.17 and its highest was €0.51 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is €3.62M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 79 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in DE:G1G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―